Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (NQ: APTO )

3.620 +0.140 (+4.02%)
Streaming Delayed Price Updated: 12:58 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,409
Open 3.690
Bid (Size) 3.620 (1)
Ask (Size) 3.790 (1)
Prev. Close 3.480
Today's Range 3.500 - 3.860
52wk Range 2.394 - 51.61
Shares Outstanding 93,653,662
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's session
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Here are the top movers in Wednesday's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill

Performance

YTD
-48.76%
-48.76%
1 Month
-34.17%
-34.17%
3 Month
-34.38%
-34.38%
6 Month
-67.30%
-67.30%
1 Year
-91.96%
-91.96%

More News

Read More
Traders are paying attention to the gapping stocks in Wednesday's session.
Via Chartmill
Thursday's session: most active stocks
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill
Top movers in Thursday's session
Via Chartmill
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
From Aptose Biosciences, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session.
Via Chartmill
Here are the top movers in Wednesday's session.
Via Chartmill
Wednesday's session: gap up and gap down stocks
Via Chartmill
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks Likely To Open Lower Following Fresh Records From Previous Session: Expert Says, 'Don't Be Scared Of New Highs'
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
Via Chartmill
Aptose Announces Reverse Share Split
From Aptose Biosciences, Inc.
Via GlobeNewswire
US Stocks Likely To Open Higher Amid Ukraine Peace Talk Hopes As Russian, American Officials Meet
Via Benzinga
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Thursday's pre-market session: top gainers and losers
Via Chartmill
These stocks are the most active in today's session
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Via Chartmill
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.